Imbruvica
AZ says Calquence is a safer drug than Imbruvica
Phil Taylor
AbbVie, AstraZeneca, BTK inhibitor, Calquence, chronic lymphocytic leukaemia, Imbruvica, Johnson & Johnson, Oncology
0 Comment
ASH: Lilly builds case for its BTK drug LOXO-305 in lymphoma
Phil Taylor
AbbVie, American Society of Haematology, BTK inhibitor, Eli Lilly, Imbruvica, Johnson & Johnson, non-Hodgkin lymphoma
0 Comment
Market Access/ News/ News/ News/ Oncology
AbbVie, J&J embed Imbruvica deeper in CLL therapy with new approval
Phil Taylor
AbbVie, chronic lymphocytic leukaemia, Imbruvica, Johnson & Johnson, Oncology
0 Comment
News/ News/ News/ Oncology/ R&D
BeiGene’s Brukinsa fails to beat AbbVie/J&J’s Ibrutinib in WM
Richard Staines
AbbVie, BeiGene, Brukinsa, Imbruvica, Johnson & Johnson
0 Comment
ASH19: AZ’s Calquence throws gauntlet down to Imbruvica
Phil Taylor
AbbVie, AstraZeneca, Calquence, chronic lymphocytic leukaemia, Haematology, Imbruvica, Johnson & Johnson
0 Comment
FDA nod for AZ’s Calquence sets up new Imbruvica showdown
Phil Taylor
AbbVie, AstraZeneca, BeiGene, Brukinsa, BTK inhibitor, Calquence, chronic lymphocytic leukaemia, Imbruvica, Johnson & Johnson
0 Comment
AbbVie and J&J claim new Imbruvica okay in US
Phil Taylor
AbbVie, CLL, Imbruvica, Johnson & Johnson
0 Comment